Overview of Adenotonsillar Hypertrophy, Management Strategies

Sami Ayyadah Ghareeb Alshammari, Atheer Musaed Aljuhani, Abdullah Ahmed Alkhalaf, Abdulmohsen Saad Alghassab, Ali M Alshdokhi, Hamoud Khalid Alshaya, Yossef Fahad Khaled Alshammari

Abstract:

This article reviews the pathophysiology and symptoms of AH. Current treatment options are considered the increasing rate of investigations on non-surgical alternatives for AH, surgery and the importance of the treatment of AH. We conducted a searches of electronic databases (PubMed, Emabse), and hand searches of bibliographies of relevant articles and gray literature searches up to March 2018, for all studies concerning, Adenotonsillar hypertrophy. Adenotonsillar hypertrophy is common problems in the pediatric and can set off symptoms such as mouth breathing, nasal congestion, hyponasal speech, snoring, and obstructive sleep apnea (OSA), in addition to chronic sinusitis and recurring otitis media. A lot more significant long-lasting sequelae, usually additional to OSA, include neurocognitive irregularities (e.g. habits and learning problems, poor focus span, hyperactivity, belowaverage intelligence ratio); cardiovascular morbidity (e.g. reduced best ventricular ejection fraction, left ventricular hypertrophy, raised diastolic blood pressure); and development failing. Adenoidectomy (with tonsillectomy in instances of adenotonsillar hypertrophy) is the usual management approach for patients with AH. Potential problems have set off the investigation of non-surgical choices. Evidence of a pathophysiologic link in between AH and allergic reaction recommends a viable function for intranasal corticosteroids (INS) in the management of patients with AH.

Introduction:

Adenotonsillar hypertrophy (AH) is considered as the commonest disorder and source of upper respiratory blockage among children. It leads to a range of temporary and long-term signs and symptoms. Temporary symptoms consist of mouth breathing, nasal congestion, hyponasal speech, snoring, obstructive sleep apnea (OSA), chronic sinus problems and recurring otitis media [1].Long-lasting symptoms, on the various other hand, are a series of significant complications related to OSA consisting of development failing, cardio morbidity and neurocognitive abnormalities such as low intelligence ratio, learning and behavioral problems, hyperactivity and poor attention span [1].

It was additionally found that children with resolution of OSA abnormalities experienced an adjustment in the total amount and Low density lipoprotein (LDL)- cholesterol levels. This searching for supports the theory that turnaround of OSA might additionally turn around the development of dyslipidemia with time. Dyslipidemia is a vital effects for the future cardiovascular disease (CVD) threat [2].

OSA, defined by recurring boosts in upper airway resistance and collapse, is thought about an usual issue in youngsters with an occurrence of 1-3% [2], [3].It is in fact the leading cause of massive morbidity, predominantly affecting the central nervous system (CNS) and cardiovascular system [4].AH remains the commonest cause of OSA in youngsters and its association with OSA has been well documented in previous researches [5], [6].

Tonsillectomy and adenoidectomy are normal approaches for patients with AH. Although these treatments have a crucial function in relieving obstructive symptoms in patients with OSA, they might lead to some serious complications such as bleeding (4-5%) and postoperative respiratory system compromise (27%) specifically among younger children [7], [8].Hence, regarding this strength, non-surgical treatments have attracted a great deal of attention as the alternatives. In order to implement non-surgical treatments, recognizing pathophysiology of AH is mandatory. Recently, several studies have investigated the etiology of the condition. According to these searching's for, a possible microbial and inflammatory etiology has been suggested for AH [9], [10].Kids with OSA, experience a combination of oxidative stress, inflammation, autonomic activation, and disruption of sleep homeostasis [2].The microbial involvement of AH was suggested based upon a boost in lymphocytes within the tonsils and adenoids. It was confirmed by locating a majority of pathogenic bacteria such as Haemophilus influenzae and other B-lactamase-producing microorganisms in hypertrophied tonsils and adenoids [11].Many studies have shown the efficacy of broad-spectrum anti-biotics in renovation of symptoms and difficulties of AH and OSA [12], [13].

The role of inflammatory consider AH and OSA has been suggested by the enhanced expression of various arbitrators of inflammatory responses in tonsils and an appropriate reaction to anti-inflammatory representatives such as corticosteroids [14], [15].On top of that, finding a great deal of steroid receptors and mRNA in adenoid tissue has supported the participation of inflammatory factors in AH [16].Nasal corticosteroids have been shown to reduce mobile spreading and manufacturing of pro-inflammatory cytokines in a tonsil/adenoid mixed-cell society system [15].As necessary, some research studies revealed the efficiency of nasal corticosteroids in treatment of AH and OSA [17], [18].

This article reviews the pathophysiology and symptoms of AH. Current treatment options are considered the increasing rate of investigations on non-surgical alternatives for AH, surgery and the importance of the treatment of AH.

Methodology:

We conducted a searches of electronic databases (PubMed, Emabse), and hand searches of bibliographies of relevant articles and gray literature searches up to March 2018, for all studies concerning, Adenotonsillar hypertrophy. We included all types of studies and we limited our search to only English published articles.

Discussion:

- **Pathophysiology**

The tonsils comprise 3 masses of tissue: the lingual tonsil, the pharyngeal (adenoid) tonsil, and the palatine or faucial tonsil. Each tonsil includes lymphoid tissue covered by breathing epithelium that is invaginated into crypts. Along with creating lymphocytes, the tonsils also manufacture immunoglobulins. Due to the fact that they are the first lymphoid aggregates in the aerodigestive tract, the tonsils are assumed to contribute in resistance. Although healthy tonsils provide immune defense, diseased tonsils are less reliable at immune features. Infected tonsils are related to lowered antigen transportation, decreased antibody production above baseline levels, and chronic bacterial infection [19].

- **Symptoms of Adenotonsillar Hypertrophy**

Symptoms of tonsil hypertrophy

Enlarged tonsils prevail in kids, and in many cases there are no obvious signs and symptoms. Nonetheless, when tonsil hypertrophy is severe, kids generally experience some of the following signs and symptoms [20]:

-Voice changes: as a result of swollen tissue near the vocal chords, the voice might be somewhat changed.

-Difficulty swallowing: the enlarged tissue of the tonsils can come to be obstructive and hinder ingesting of certain foods.

-Loss of cravings: when ingesting food is difficult or painful, lots of children hesitate to eat.

-Halitosis: because of infections of the tonsils, poor breath frequently impacts children with tonsil hypertrophy

-Snoring: hypertrophic tonsils could obstruct the airways, making breathing throughout rest harder.

-OSA: in severe situations of tonsil hypertrophy, rest apnea can occur. This results from blocked respiratory tracts. Sleep apnea is a major condition that can potentially create pulmonary hypertension and hypertrophy of the best side of the heart.

-Frequent ear infections: the enlarged tonsils could obstruct the eustachian tubes and impede drainage. This could cause fluid accumulation behind the tympanum and ear infections.

-Chronic sinusitis: hypertrophic tonsils and surrounding tissue could prevent proper drainage from the sinus cavities. Mucus becomes trapped and infections could establish. Symptoms such as blockage, pressure, and tiredness are common with sinus problems.

Symptoms of adenoid hypertrophy

The symptoms of adenoid hypertrophy are commonly just like those of tonsil hypertrophy and happen when the bigger adenoid tissue develops an obstruction [20]:

-Mouth breathing: as a result of blocked nasal respiratory tracts, children with adenoid hypertrophy are usually required to take a breath through their mouth. If mouth breathing occurs for a prolonged duration of time, orthodontic concerns could occur.

-Runny nose: because mucous could not drain correctly via the back of the nasal tooth cavity, mucous and secretions exit with the nostrils.

-Snoring and sleep apnea: the blocked respiratory tracts caused by the bigger adenoid tissue could disrupt breathing throughout sleep.

-Chronic sinusitis: when bigger adenoids obstruct the nasal flows, the sinus cavities could not drain correctly. The accumulation of mucous brings about inflammation of the lining and frequently infections.

-Eustachian tube disorder: when bigger adenoids prevent proper drainage from the eustachian tubes, fluid collects behind the eardrum.

- **Treatment**

Management of obstructive sleep problems could be surgical, medical, or airway placement therapy (Table 1). Treatment must be embellished based after the age, background, severity of

obstructive episodes, and wellness assessment. Clinical therapy consists of 1) weight decline and nutritional treatments, 2) nasal continual favorable airway pressure, and 3) drugs such as acetazolamide, steroids, and theophylline. Surgical interventions are led towards eliminating the website of airway obstruction. Adenotonsillar hypertrophy is one of the most usual factor for obstructive sleep apnea, and adenotonsillectomy is just one of the most frequently done therapy. Care should be used to obtain rid of all adenoid tissue at the degree of the choanae to alleviation the nasal obstruction and quit any type of kind of future regrowth of the adenoid. Various other surgical interventions consist of orthognathic surgical therapy, uvulopalatopharyngoplasty, tongue reduction, and tracheotomy [21], [22].These procedures could be considered in patients with a craniofacial abnormality after a mindful assessment by an interdisciplinary group approach.

Table1. Treatment options for Upper Airway Obstruction

Medical: Diet and weight reduction Nasal positive airway pressure Medications (steroid, acetazolamide, protriptyline)	**Surgery: removal of obstruction:** Adenoidectomy Tonsillectomy Adenotonsillectomy Uvulopalatopharyngoplasty Septoplasty Nasal polypectomy Tongue reduction
Intervention: bypass of obstruction: Nasopharyngeal airway Tracheotomy	**Surgery: positional manipulation of airway:** Hyoidplasty Orthognathic surgery Craniofacial surgery

Surgery

Surgery is thoroughly authorized as first-line therapy for patients with symptomatic AH or adenotonsillar hypertrophy associated to significant morbidity- adenoidectomy in kids with

severe signs and symptoms of AH [24], [23] and adenotonsillectomy in kids with sleep apnea due to

adenotonsillar hypertrophy [24].Researches in OSA report a cumulative remedy rate of 80% [26].A retrospective review over 2 year in 206 children (indicate age 6.5 years; range 2- 17 years) that underwent adenoidectomy at a tertiary care center recommend that some adenoid regrowth takes place in 15- 25% of patients, although scientifically substantial adenoid regrowth causing nasal obstruction is a lot less normal [27].There is restricted details on adenoid regrowth and connection with age. In the evaluation merely gone over, in the sample that experienced appointment on follow-up (n = 36), department by age often of adenoidectomy yielded no organization with adenoid regrowth on subsequent (3- 5 years after surgical therapy) [27].In a similar way, in a cross-sectional follow-up research of 175 kids (recommend age 5.9 years, s.d. 3.0) who had in fact gone with adenoidectomy 2- 5 years formerly, the connection in between age at follow-up and the degree of nasopharyngeal blockage by adenoid tissue (in the 35 patients figured out) was incredibly weak and not statistically significant (Pearson r =)0.1, P = 0.5) [28].On the other hand, results of a possible follow-up 12-24 months after adenoidectomy among 150 youngsters (age range 3-15 years) indicated a relationship between adenoidal regrowth and patient age (P = 0.048) among youngsters 5 years or younger [29].Of note, a methodical review ended that the efficiency of tonsillectomy and adenoidectomy for pediatric OSA has yet to be entirely established by possible, randomized tests and that efficacy under routine issues has not been determined [26].Adenoidectomy and adenotonsillectomy are connected with possible threats and complications.About 1% of youngsters experience instant post-operative or late bleeding [28].This contrasts with approximately 2.6% (significant blood loss) for orthopedic surgical therapy, 3-11% for cardiac surgery, and 6% for nasal surgery (polypectomy, antrostomy,

and useful endoscopic sinus operation). An extra practical hazard is that the extremely early elimination of adenoidal tissue could have an unfavorable result on immune function. Non-surgical techniques for reducing the dimension of the adenoids are currently restricted. Medication treatment choices are thus being gone after as an alternative to surgery for AH to maintain immunologically energised tissue and remain free from the dangers intrinsic in adenoidectomy, which does not take care of the underlying inflammation implicated in AH.

Treatment with intranasal corticosteroids

Existing standards recommend INS as first-line therapy for AR, and INS may be efficient in symptomatic AH by minimizing inflammatory arbitrators implicated in the allergy [31]. Glucocorticoid receptor (GCR) expression in adenotonsillar tissue in kids with OSA showed a high GCR-a/GCR-b percentage and greater expression of GCR-a in patients with OSA vs. consistent upper airway infection, which is medically substantial because boosted GCR-b expression might be associated with improved resistance to decreases of swelling by topical steroids [32].In a team of 31 youngsters with AH and seasonal AR, 3 months of treatment with INS and antihistamine substantially lowered AH (as determined by endoscopy and acoustic rhinometry) and obstructive airway signs and symptoms [33] Like AH, AR is associated to sleep disruptions second to nasal blockage [34].The effectiveness of INS in lowering these AR-associated sleep troubles has been shown in several clinical trials [35].Intranasal corticosteroids in combination with antihistamine and antibiotic have likewise revealed efficiency in decreasing AH relevant to rhinosinusitis in a small pediatric study.As discussed formerly, symptomatic augmentation of adenoidal tissue has been associated with microbial stimulations as a trigger, and adherent biofilms have been uncovered on the surface of frequently swollen tonsils and adenoids. Among a variety of suggested systems of INS in reduction of adenoid dimension and

inflammation involves topical steroid alteration of adenoid bacterial flora, hence minimizing the significance of the adenoid as a nidus for infection. Based upon these observations, a variety of scientific research studies and a metaanalysis [36] have been executed to determine the effectiveness of INS in regulating AH. Five randomized examinations met the enhancement requirements for a Cochrane assessment, which discovered that 4 tests revealed significant efficiency for INS in improving nasal clog and reducing adenoid size in kids with moderate-to-severe AH. The reviewers concluded that the excepting research study, which exposed a fivefold decline in adenoid measurement with INS, could have been insufficiently powered to attain analytical importance due its small example dimension [36].

The efficacy of azithromycin and fluticasone in treatment of AH-related symptoms

As discussed, numerous research studies have supported the duty of inflammatory variables and bacterial participations in the etiology of AH due to the results of corticosteroids and antibiotics in improving symptoms and issues [12], [13], [18], [17]. In this research, we selected azithromycin as an anti-bacterial therapy. It is considered as a broad-spectrum antibiotic with appropriate task versus Streptococcus pneumoniae, Haemophilus influenzae, and other b-lactamase-producing organisms. It additionally keeps high tissue focus particularly in the tonsil [37].Utilizing azithromycin with our method would certainly make bacterial resistance unlikely to occur [12].

Although proof sustain the safety and security of nasal corticosteroids in AH therapy amongst kids as a result of restricted or missing negative effects and regional anti-inflammatory task on the upper airways, current research studies have shown that lasting use some corticosteroids may have suppressive impacts on hypothalamic-pituitary-adrenal axis [38].

Don et al. showed azithromycin as helpful in management of AH and OSA because of its modest effects. It could likewise trigger temporary improvement of OSA symptoms in patients with extreme AH that are prospect for surgical intervention. They ended that it could not be a correct choice to surgery [12].

In the study [43], azithromycin had an appropriate impact on all AH-related variables 1 and 8 weeks after the treatment. Nevertheless, as compared to 1 week after the treatment, grades of some symptoms such as mouth breathing, snoring, hyponasal speech and sleep apnea were not reduced or even adversely enhanced in a significant method after 8 weeks. As a result, although both post-treatment dimensions revealed renovations in symptoms contrasted to the initial standing, temporary effectiveness of the antibiotic was far more substantial than its lasting impacts. Nonetheless, more studies with larger sample sizes and longer follow-up durations are needed for even more exact conclusion in this field.

Brouillette et al. explored the efficiency of fluticasone nasal spray for pediatric OSA. They revealed that a 6-week course of fluticasone management lowered the intensity of pediatric OSA signs. They ended that nasal corticosteroids more than likely affect the structural component of OSA by lowering the inspiratory upper airway resistance at the nasal, adenoidal, or tonsillar degrees [18].

Burton et al. released an evaluation short article regarding the efficacy of nasal corticosteroids for nasal airway blockage in children with modest to severe adenoidal hypertrophy. They reviewed 5 randomized trials and concluded that nasal corticosteroids could considerably boost nasal obstruction symptoms in this team of patients and the renovation could be connected with a reduction in adenoid size [39].

Fluticasone in the research study [43] had an appropriate impact on enhancing AH-related symptoms and grade of obstruction, with the exception of tonsillar hypertrophy. Nonetheless, although the intensity of mouth breathing improved 1 and 8 weeks after the intervention compared with initial measurements, significant enhancements were not observed after 8 weeks compared with the initial week. Lepcha et al. reported beclomethasone, a nasal corticosteroid, not to be valuable in therapy of adenoid hypertrophy in kids [40].Ciprandi et al. reviewed the effects of intranasal flunisolide on AH and indicated that the therapy was related to significant decrease of AH degree. They wrapped up that an 8-week treatment with intranasal flunisolide would prevent the rate of adenoidectomy [41].Varricchio et al. analyzed the long-term (12 months) impacts of intranasal flunisolide on AH. They similarly reported the drug to be helpful in avoiding adenoidectomy [42].

Findings of the research study [43] showed that azithromycin and fluticasone could be suitably utilized for mild and moderate situations of AH. The medications could also be administered for patients with serious AH for which surgery is high risk. Nevertheless, azithromycin seemed extra efficient than fluticasone nasal spray in boosting AH-related symptoms. On the various other hand, long-term administration of nasal corticosteroids with lower bioavailability would be a lot more efficient in this filed.

Conclusion:

Adenotonsillar hypertrophy is common problems in the pediatric and can set off symptoms such as mouth breathing, nasal congestion, hyponasal speech, snoring, and obstructive sleep apnea (OSA), in addition to chronic sinusitis and recurring otitis media. A lot more significant long-lasting sequelae, usually additional to OSA, include neurocognitive irregularities (e.g. habits and learning problems, poor focus span, hyperactivity, belowaverage intelligence ratio); cardiovascular morbidity (e.g. reduced best ventricular ejection fraction, left ventricular hypertrophy, raised diastolic blood pressure); and development failing. Adenoidectomy (with tonsillectomy in instances of adenotonsillar hypertrophy) is the usual management approach for patients with AH. Potential problems have set off the investigation of non-surgical choices. Evidence of a pathophysiologic link in between AH and allergic reaction recommends a viable function for intranasal corticosteroids (INS) in the management of patients with AH.

Reference:

1. Scadding G. Non-surgical treatment of adenoidal hypertrophy: The role of treating IgE-mediated inflammation. Pediatr Allergy Immunol. 2010;21(8):1095–106.
2. Kelishadi R, Nilforoushan N, Okhovat A, Amra B, Poursafa P, Rogha M. Effects of adenoidectomy on markers of endothelial function and inflammation in normal-weight and overweight prepubescent children with sleep apnea. J Res Med Sci. 2011;16(Special Issue):386–94.
3. Lumeng JC, Chervin RD. Epidemiology of pediatric obstructive sleep apnea. Proc Am Thorac Soc. 2008;5(2):242–52.
4. Capdevila OS, Kheirandish-Gozal L, Dayyat E, Gozal D. Pediatric obstructive sleep apnea: complications, management, and long-term outcomes. Proc Am Thorac Soc. 2008;5(2):274–82.

5. Greenfeld M, Tauman R, DeRowe A, Sivan Y. Obstructive sleep apnea syndrome due to adenotonsillar hypertrophy in infants. Int J Pediatr Otorhinolaryngol. 2003;67(10):1055–60.
6. Katz ES, D'Ambrosio CM. Pathophysiology of pediatric obstructive sleep apnea. Proc Am Thorac Soc. 2008;5(2):253–62.
7. Peterson J, Losek JD. Post-tonsillectomy hemorrhage and pediatric emergency care. Clin Pediatr (Phila) 2004;43(5):445–8.
8. Stuck BA, Gotte K, Windfuhr JP, Genzwurker H, Schroten H, Tenenbaum T. Tonsillectomy in children. Dtsch Arztebl Int. 2008;105(49):852–60.
9. Jeong JH, Lee DW, Ryu RA, Lee YS, Lee SH, Kang JO, et al. Bacteriologic comparison of tonsil core in recurrent tonsillitis and tonsillar hypertrophy. Laryngoscope. 2007;117(12):2146–51.
10. Serpero LD, Kheirandish-Gozal L, Dayyat E, Goldman JL, Kim J, Gozal D. A mixed cell culture model for assessment of proliferation in tonsillar tissues from children with obstructive sleep apnea or recurrent tonsillitis. Laryngoscope. 2009;119(5):1005–10.
11. Brook I, Shah K, Jackson W. Microbiology of healthy and diseased adenoids. Laryngoscope. 2000;110(6):994–9.
12. Don DM, Goldstein NA, Crockett DM, Ward SD. Antimicrobial therapy for children with adenotonsillar hypertrophy and obstructive sleep apnea: a prospective randomized trial comparing azithromycin vs placebo. Otolaryngol Head Neck Surg. 2005;133(4):562–8.
13. Sclafani AP, Ginsburg J, Shah MK, Dolitsky JN. Treatment of symptomatic chronic adenotonsillar hypertrophy with amoxicillin/clavulanate potassium: short- and long-term results. Pediatrics. 1998;101(4 Pt 1):675–81.
14. Kim J, Bhattacharjee R, Dayyat E, Snow AB, Kheirandish-Gozal L, Goldman JL, et al. Increased cellular proliferation and inflammatory cytokines in tonsils derived from children with obstructive sleep apnea. Pediatr Res. 2009;66(4):423–8.
15. Kheirandish-Gozal L, Serpero LD, Dayyat E, Kim J, Goldman JL, Snow A, et al. Corticosteroids suppress in vitro tonsillar proliferation in children with obstructive sleep apnoea. Eur Respir J. 2009;33(5):1077–84.
16. Goldbart AD, Veling MC, Goldman JL, Li RC, Brittian KR, Gozal D. Glucocorticoid receptor subunit expression in adenotonsillar tissue of children with obstructive sleep apnea. Pediatr Res. 2005;57(2):232–6.
17. Demain JG, Goetz DW. Pediatric adenoidal hypertrophy and nasal airway obstruction: reduction with aqueous nasal beclomethasone. Pediatrics. 1995;95(3):355–64.
18. Brouillette RT, Manoukian JJ, Ducharme FM, Oudjhane K, Earle LG, Ladan S, et al. Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea. J Pediatr. 2001;138(6):838–44.
19. Drake AF (2015) Tonsillectomy. In: Meyers AD (ed) Medscape. http://reference.medscape.com/article/872119-overview#showall. Accessed 3 Jan 2016
20. Trimble MV (2016) Adenoid and tonsil hypertrophy. http:// dfwsinus.com/nasal-airway-obstruction/adenoid-tonsil-hyper trophy/. Accessed 3 Jan 2016

21. Shapiro J, Strome M, Crocker AC: Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol 94:458- 461, 1985.
22. Seid AB, Martin PJ, Pransky SM, Kearns DB: Surgical therapy of obstructive sleep apnea in children with severe mental insufficiency. Laryngoscope 100:507-515, 1990.
23. Brodsky L. Modern assessment of tonsils and adenoids. Pediatr Clin North Am 1989: 36: 1551–69.
24. Maw AR, Parker A. Surgery of the tonsils and adenoids in relation to secretory otitis media in children. Acta Otolaryngol Suppl 1988: 454: 202–7.
25. American Academy of Pediatrics. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002: 109: 704–12.
26. Lipton AJ, Gozal D. Treatment of obstructive sleep apnea in children: do we really know how? Sleep Med Rev 2003: 7: 61–80.
27. Joshua B, Bahar G, Sulkes J, Shpitzer T, Raveh E. Adenoidectomy: long-term follow-up. Otolaryngol Head Neck Surg 2006: 135: 576–80.
28. Buchinsky FJ, Lowry MA, Isaacson G. Do adenoids regrow after excision? Otolaryngol Head Neck Surg 2000: 123: 576–81.
29. Lesinskas E, Drigotas M. The incidence of adenoidal regrowth after adenoidectomy and its effect on persistent nasal symptoms. Eur Arch Otorhinolaryngol 2009: 266: 469–73.
30. Windfuhr JP, Chen YS, Remmert S. Hemorrhage following tonsillectomy and adenoidectomy in 15,218 patients. Otolaryngol Head Neck Surg 2005: 132: 281–6.
31. Rak S, Jacobson MR, Sudderick RM, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994: 24: 930–9.
32. Hamilos DL, Leung DY, Muro S, et al. GRb expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone. J Allergy Clin Immunol 2001: 108: 59–68.
33. Modrzyn´ski M, Zawisza E, Mazurek H. The influence of medical treatment of the perennial allergic rhinitis on the adenoid size in children. Otolaryngol Pol 2006: 60: 543–50.
34. Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998: 101: 633–7.
35. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003: 58: 380–5.
36. Zhang L, Mendoza-Sassi RA, Ce´sar JA, Chadha NK. Intranasal corticosteroids for nasal airway obstruction in children with moderate to severe adenoidal hypertrophy. Cochrane Database Syst Rev 2008: 16: CD006286.

37. Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother. 1993;37(2):314–6.
38. Mehle ME. Are nasal steroids safe? Curr Opin Otolaryngol Head Neck Surg. 2003;11(3):201–5.
39. Burton MJ, Derkay CS, Rosenfeld RM. Extracts from The Cochrane Library: intranasal corticosteroids for moderate to severe adenoidal hypertrophy. Otolaryngol Head Neck Surg. 2009;140(4):451–4.
40. Lepcha A, Kurien M, Job A, Jeyaseelan L, Thomas K. Chronic adenoid hypertrophy in children Çö is steroid nasal spray beneficial? Indian Journal of Otolaryngology and Head & Neck Surgery. 2002;54(4):280–4.
41. Ciprandi G, Varricchio A, Capasso M, Varricchio AM, De LA, Ascione E, et al. Intranasal flunisolide treatment in children with adenoidal hypertrophy. Int J Immunopathol Pharmacol. 2007;20(4):833–6.
42. Varricchio A, Tortoriello G, Capasso M, De LA, Marchisio P, Varricchio AM, et al. Prevention of surgery in children with adenoidal hypertrophy treated with intranasal flunisolide: a 12-month follow-up. J Biol Regul Homeost Agents. 2009;23(2):95–101.